Browsing by Author "Kilicdag, Esra B."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Extended culture of cleavage-stage embryos in vitrified-thawed cycles may be an alternative to frozen and thawed blastocysts during in vitro fertilization
    (2021) Aytac, Pinar C.; Kilicdag, Esra B.; 34308730
    Aim We compared the clinical outcomes of vitrified-thawed cycles during in vitro fertilization (IVF) for frozen and thawed blastocysts compared to cleavage-stage embryos that were frozen, thawed and extended culture to the blastocyst stage. Material and methods Between January 2014 and December 2016, 908 frozen-thawed cycles were included in the study. After removing cycles that met exclusion criteria, clinical outcomes for 355 cleavage-stage embryos with extended blastocyst culture (Group I) were compared with 279 frozen and thawed blastocysts (Group II). Results Cryo-survival rate of the two groups were similar (96.7% versus 95.0%). Implantation rates (28.9% versus 22.4%, p = .04) and clinical pregnancy rates (37.2% versus 27.9%, p = .03) were higher in Group I. Pregnancy, live birth and abortus rates were similar in both groups. Although overall abortus rates were similar in both groups, abortus rates before 12 weeks of gestation were higher in Group I, and chemical abortus rates were higher in Group II (p = .03, p = .04). Weeks of gestation at birth and birth weight were similar in both groups. Conclusions The use of extended blastocyst culture of cleavage-stage embryos was not inferior to frozen and thawed blastocysts. Freezing at the cleavage-stage can provide similar cryo-survival rates than blastocyst vitrification. Vitrifying surplus or all embryos for storage at the cleavage-stage allows higher implantation and clinical pregnancy rates. But after abortus, live birth rates were similar in both groups.
  • No Thumbnail Available
    Item
    GNRH Agonists and Antagonists in Rescue for Cyclophosphamide-Induced Ovarian Damage: Friend or Foe?
    (2015) Parlakgumus, Huriye A.; Kilicdag, Esra B.; Bolat, Filiz A.; Haydardedeoglu, Bulent; Parlakgumus, Alper; 0000-0002-0942-9108; 0000-0003-2031-7374; 25472738; AAK-8872-2021; HJZ-1654-2023
    To find out if GnRH agonist (GnRHa) and GnRH antagonist (GnRHant) offer ovarian protection from cyclophosphamide (Cyc) and if AMH expression is affected. This experimental study was conducted in Baskent University Animal research laboratory and 66 virgin Wistar albino rats were assigned to six groups. The control group received intraperitoneal saline injection. The GnRHa group had a single dose of leuprolide acetate (1 mg/kg) 28 days prior to saline injection. The GnRHant group had a single dose of cetrorelix acetate (0.1 mg/kg) 1 h prior to saline injection. The Cyc group had a single intraperitoneal dose of Cyc (75 mg/kg). The GnRHa+Cyc group had a single dose of leuprolide acetate (1 mg/kg) 28 days prior to Cyc (75 mg/kg). The GnRHant+Cyc group had single dose of cetrorelix acetate (0.1 mg/kg) 1 h prior to Cyc (75 mg/kg). At day 35, the animals were euthanized, and their ovaries were removed. Primordial follicles were counted and AMH expression was determined. The Kruskal-Wallis, chi (2), or Fisher's exact test was used where appropriate. p < 0.05 was considered statistically significant. PMF count was reduced in GnRHant (p < 0.01) and Cyc (p < 0.01) groups. Cyc, GnRHa+Cyc and GnRHant+Cyc groups had similar numbers of PMF. AMH expression was reduced in Cyc, GnRHa+Cyc and GnRHant+Cyc groups (p < 0.01). Neither GnRHa nor GnRHant can offer protection against Cyc-induced damage. GnRHant itself reduces the number of primordial follicles.